The Commercial Appeal

Antiquated privacy rule blocks addiction treatment options

- Your Turn Guest columnist

Opioid misuse has reached epidemic proportion­s in the United States; and for the first time since the 1960s life expectancy in the U.S. has dropped for two years in a row. To combat the opioid crisis, health care providers must have access to substance use disorder records of their patients to ensure each person is provided with safe, effective treatment and care.

However, a federal regulation, written in 1972 and known as 42 CFR Part 2, separates a patient’s history of addiction from the rest of their health record, making it difficult for providers to deliver the care a patient may need. When this law was enacted more than four decades ago, it was done so for the purpose of ensuring that those who sought addiction treatment were able to do so privately.

However, in today’s health care landscape – of electronic health records and extensive patient privacy laws – this 1972 law adds an additional layer of consent. In laymen’s terms, this means that unless a patient exBecause

More viewpoint

pressly provides additional consent for their record, a treating provider cannot view that record or share that informatio­n with other treating providers.

As a provider of behavioral health, we’ve had patients referred to us by a physician for treatment of depression or anxiety. However, in some of these cases, we identify that this patient also is struggling to overcome addiction. Even though we may have consent to share informatio­n from that patient’s health record, if it’s related to addiction we need a separate consent. If a patient does not want to consent, that can put them at risk for receiving dangerous amounts or combinatio­ns of prescripti­ons.

Ultimately, this antiquated rule slows the coordinati­on of treatment, inhibits provider collaborat­ion and can put patients’ lives at risk. Without transparen­cy, providers may accidental­ly pose safety threats to their patients with substance use disorders because of risk of multiple drug interactio­ns.

of this, Centerston­e has joined the Partnershi­p to Amend Part 2. The Partnershi­p is a coalition of more than 40 diverse organizati­ons committed to aligning 42 CFR Part 2 with HIPAA for the limited purposes of health care treatment, payment and operations and to strengthen existing protection­s against the use of substance use disorder records in civil and criminal proceeding­s to ensure patient privacy is upheld. A bill known as the “OPPS Act,” or the Overdose and Patient Safety Act (H.R. 3545), can accomplish this much-needed objective of disclosing patient informatio­n for limited means – associated with their treatment – while simultaneo­usly protecting privacy.

In the midst of the nation’s largest drug crisis, modernizin­g our nation’s health IT infrastruc­ture is a critical step in delivering timely, lifesaving care. In doing this, along with shoring up protection­s for patient privacy, providers will be better equipped to deliver safe, whole-person care.

David Guth is CEO of Centerston­e, a nonprofit organizati­on that provides mental health and substance abuse treatment, education and support to communitie­s in Tennessee and elsewhere.

For more commentary, go to commercial­appeal.com/opinion/

 ?? David Guth ??
David Guth

Newspapers in English

Newspapers from United States